208 related articles for article (PubMed ID: 24325789)
1. Molecular biology of high-grade gliomas: what should the clinician know?
Hofer S; Rushing E; Preusser M; Marosi C
Chin J Cancer; 2014 Jan; 33(1):4-7. PubMed ID: 24325789
[TBL] [Abstract][Full Text] [Related]
2. Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas.
Siegal T
Adv Tech Stand Neurosurg; 2016; (43):91-108. PubMed ID: 26508407
[TBL] [Abstract][Full Text] [Related]
3. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T
Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037
[TBL] [Abstract][Full Text] [Related]
4. Molecular Characteristics of Thalamic Gliomas in Adults.
Wang T; Niu X; Gao T; Zheng L; Qiu Y; Mao Q
J Mol Neurosci; 2021 Aug; 71(8):1598-1604. PubMed ID: 33523385
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of molecular biomarkers in gliomas.
Siegal T
J Clin Neurosci; 2015 Mar; 22(3):437-44. PubMed ID: 25533211
[TBL] [Abstract][Full Text] [Related]
7. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas.
Yi L; Fan X; Li J; Yuan F; Zhao J; Nistér M; Yang X
Aging (Albany NY); 2021 Jan; 13(3):3645-3660. PubMed ID: 33493139
[TBL] [Abstract][Full Text] [Related]
8. The association between
Okita Y; Shofuda T; Kanematsu D; Yoshioka E; Kodama Y; Mano M; Kinoshita M; Nonaka M; Fujinaka T; Kanemura Y
Clin Radiol; 2020 Aug; 75(8):622-628. PubMed ID: 32321646
[TBL] [Abstract][Full Text] [Related]
9. Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study.
Huang L; Jiang T; Yuan F; Li GL; Cui Y; Liu EZ; Wang ZC
Neuropathol Appl Neurobiol; 2009 Aug; 35(4):367-379. PubMed ID: 19019173
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.
Juratli TA; Kirsch M; Geiger K; Klink B; Leipnitz E; Pinzer T; Soucek S; Schrock E; Schackert G; Krex D
J Neurooncol; 2012 Dec; 110(3):325-33. PubMed ID: 23015095
[TBL] [Abstract][Full Text] [Related]
12. A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival.
Das P; Puri T; Jha P; Pathak P; Joshi N; Suri V; Sharma MC; Sharma BS; Mahapatra AK; Suri A; Sarkar C
J Clin Neurosci; 2011 Jan; 18(1):66-70. PubMed ID: 20888234
[TBL] [Abstract][Full Text] [Related]
13. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.
Mellai M; Monzeglio O; Piazzi A; Caldera V; Annovazzi L; Cassoni P; Valente G; Cordera S; Mocellini C; Schiffer D
J Neurooncol; 2012 May; 107(3):617-31. PubMed ID: 22287028
[TBL] [Abstract][Full Text] [Related]
14. Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.
Laxton RC; Popov S; Doey L; Jury A; Bhangoo R; Gullan R; Chandler C; Brazil L; Sadler G; Beaney R; Sibtain N; King A; Bodi I; Jones C; Ashkan K; Al-Sarraj S
Neuro Oncol; 2013 Dec; 15(12):1635-43. PubMed ID: 24158110
[TBL] [Abstract][Full Text] [Related]
15. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
16. The value of MGMT promote methylation and IDH-1 mutation on diagnosis of pseudoprogression in patients with high-grade glioma: A meta-analysis.
Zhou M; Niu C; Jia L; He H
Medicine (Baltimore); 2019 Dec; 98(50):e18194. PubMed ID: 31852075
[TBL] [Abstract][Full Text] [Related]
17. Molecular classification of patients with grade II/III glioma using quantitative MRI characteristics.
Bahrami N; Hartman SJ; Chang YH; Delfanti R; White NS; Karunamuni R; Seibert TM; Dale AM; Hattangadi-Gluth JA; Piccioni D; Farid N; McDonald CR
J Neurooncol; 2018 Sep; 139(3):633-642. PubMed ID: 29860714
[TBL] [Abstract][Full Text] [Related]
18. Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control.
Feyissa AM; Worrell GA; Tatum WO; Chaichana KL; Jentoft ME; Guerrero Cazares H; Ertekin-Taner N; Rosenfeld SS; ReFaey K; Quinones-Hinojosa A
Seizure; 2019 Jul; 69():283-289. PubMed ID: 31141785
[TBL] [Abstract][Full Text] [Related]
19. Infrequent RAS mutation is not associated with specific histological phenotype in gliomas.
Makino Y; Arakawa Y; Yoshioka E; Shofuda T; Minamiguchi S; Kawauchi T; Tanji M; Kanematsu D; Nonaka M; Okita Y; Kodama Y; Mano M; Hirose T; Mineharu Y; Miyamoto S; Kanemura Y
BMC Cancer; 2021 Sep; 21(1):1025. PubMed ID: 34525976
[TBL] [Abstract][Full Text] [Related]
20. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.
Wiestler B; Capper D; Hovestadt V; Sill M; Jones DT; Hartmann C; Felsberg J; Platten M; Feiden W; Keyvani K; Pfister SM; Wiestler OD; Meyermann R; Reifenberger G; Pietsch T; von Deimling A; Weller M; Wick W
Neuro Oncol; 2014 Dec; 16(12):1630-8. PubMed ID: 25028501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]